Overview

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Status:
Completed
Trial end date:
2017-12-20
Target enrollment:
Participant gender:
Summary
To assess the efficacy of intravitreal (IVT) administration of aflibercept with two different approaches of Treat and Extend dosing regimens in Japanese subjects with neovascular (wet) Age-related Macular Degeneration (wAMD) . To assess the safety of IVT administration of aflibercept with two different approaches of Treat and Extend dosing regimen in Japanese subjects with wAMD for up to 2 years.
Phase:
Phase 4
Details
Lead Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept